ACTH<sub>6-9</sub>-PGP improves memory consolidation processes in rats

Svetlana A. Dodonova, Igor' I. Bobyntsev, Andrey E. Belykh, Anton O. Vorvul

Corresponding author: Svetlana A. Dodonova (dodonovasveta@mail.ru)

Abstract

Introduction: The His-Phe-Arg-Trp sequence corresponding to the 6-9<sup>th</sup> amino acid residue of the adrenocorticotropic hormone molecule (ACTH<sub>6-9</sub>) is the critical pharmacophore of all endogenous melanocortin receptor agonists. In order to effects prolongation it may be stabilized by the addition of the amino acid sequence Pro-Gly-Pro (PGP) to the C-terminus. The aim of this work was to study the effect of ACTH<sub>6-9</sub>-PGP (HFRWPGP) on the processes of memory consolidation in the model of passive avoidance conditioning in comparison with ACTH<sub>4-7</sub>-PGP effects.

Materials and methods: The study was carried out on the model of passive avoidance conditioning. The effects of ACTH<sub>6-9</sub>-PGP were studied after its intraperitoneal injection to male Wistar rats at doses of 0.5, 5, 50, 150, and 450 μg/kg 15 minutes before the experiment, whereas the effects of ACTH<sub>4-7</sub>-PGP– under the similar conditions at doses of 50, 150, and 450 μg/kg.

Results and discussion: It was found that ACTH<sub>6-9</sub>-PGP had a pronounced stimulating effect on the memory consolidation process in the dose range from 0.5 μg/kg to 150 μg/kg, significantly increasing the latent period of an animal entering the dark chamber. Administration of ACTH<sub>4-7</sub>-PGP led to an improvement in the consolidation processes of the acquired conditioned reflex at the doses of 50 μg/kg and 450 μg/kg.

Conclusion: The range of effective doses of ACTH<sub>6-9</sub>-PGP is lower than that of ACTH<sub>4-7</sub>-PGP, which indicates the greater activity of HFRWPGP sequence in relation to memory consolidation processes and allows considering this peptide as a promising molecule for creating nootropic pharmacological drugs.

Keywords

synthetic analog of ACTH, melanocortins, memory, passive avoidance conditioning.

Introduction

Nootropic drugs are a special group of neuropsychotropie drugs, the specific effect of which is determined by their ability to improve learning and memory processes, cognitive and intellectual functions of healthy individuals, and in case of various diseases. They are used for the treatment of the psychoorganic syndromes of neurodegenerative or vascular genesis (e.g. senile dementia, including Alzheimer’s disease), craniocerebral traumas, acute and chronic disorders of cerebral circulation, including strokes, etc. Nootropic drugs administration is also recommended for healthy people when they need to improve their mental performance,
concentration, planning, and decision-making abilities (Mironov 2012).

One of the classes of regulatory peptides, currently actively studied, is melanocortins, which include adrenocorticotropic hormone (ACTH), α-, β-, and γ-melanocyte-stimulating hormones (Catania 2008; Catania et al. 2010; Eves and Haycock 2010). An important aspect of the neurotropic activity of melanocortins is their adaptive action through the effect on memory, learning, and attention. ACTH fragments, as other melanocortin peptides, have a nootropic effect and stimulate the above processes (Catania et al. 2010; Umnov et al. 2013; Clark et al. 2016; Koroleva and Myasoedov 2018; Levitskaya et al. 2019). Moreover, the His-Phe-Arg-Trp sequence corresponding to the ACTH<sub>6-9</sub> region is required for the activation of all types of melanocortin receptors (Wikberg et al. 2000; Hill and Faulkner 2017; Fridmanis et al. 2017; Palmer et al. 2017). His-Phe-Arg-Trp is known to be a critical pharmacophore (Levitskaya and Kamensky 2009; Fridmanis et al. 2017; Palmer et al. 2017; Todorovic et al. 2018) for all endogenous melanocortin receptor (MCR) agonists, i.e. it represents the structure which is necessary to ensure optimal supramolecular interactions with an appropriate biological target (Eves and Haycock 2010; Palmer et al. 2017; Todorovic et al. 2018). The structurally modified molecule (by the attachment of Pro-Gly-Pro (PGP) tripeptide sequence to its C-terminus in order to increase resistance to the action of carboxypeptidases) of this fragment also has a neurotropic effect (Levitskaya et al. 2019). However, the effect of the ACTH<sub>6-9</sub>-PGP peptide on various memory phases in a wide dose range has not yet been studied.

At the same time, the structurally close synthetic fragment ACTH<sub>4-7</sub>-PGP, which is the active substance of the pharmacological drug Semax (ACTH<sub>4-7</sub>-PGP), has similar effects (Dolotov et al. 2006, Koroleva and Myasoedov 2018, Yasenyavskaya et al. 2019). Therefore, for the purpose of structural and functional analysis of the N-terminal fragments of ACTH, it seemed necessary to study this type of neurotropic activity of the ACTH<sub>4-7</sub>-PGP molecule.

The aim of this work was to study the effects of ACTH<sub>4-7</sub>-PGP on the processes of memory consolidation in the model of passive avoidance conditioning (PAC) in comparison with the effects of ACTH<sub>6-9</sub>-PGP.

Materials and methods

Experimental animals

The studies were carried out on male Wistar rats, weighing 300–350 g, obtained from AL’KONDI Nursery (Moscow). The rats were kept under the standard vivarium conditions, with a 12-hour light regime (12 h light – 12 h darkness cycle) and controlled temperature (22±2 °C); the animals had free access to standard pelleted food and water. The study was approved by the Ethics Committee of Kursk State Medical University (Minutes No. 3 dated October 27, 2015). The conditions for keeping animals and working with them were in accordance with the principles of Directive 2010/63/EU of the European Parliament and of the Council the European Union of 22 September 2010 on the protection of animals used for scientific purposes, Rules of Laboratory Practice in the Russian Federation, approved by the Ministry of Health of the Russian Federation (Order of No. 708n dated August 23, 2010).

Study substances

The ACTH<sub>4-7</sub>-PGP peptide with the formula His-Phe-Arg-Trp-Pro-Gly-Pro (HFRWPGP) was used. The reference peptide was the structurally and functionally similar ACTH<sub>6-9</sub>-PGP peptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). The peptides were synthesized at the Institute of Molecular Genetics of Russian National Research Centre Kurchatov Institute. The purity of the substances used was 98.9% for ACTH<sub>4-7</sub>-PGP and 98.7% for ACTH<sub>6-9</sub>-PGP, according to a chromatographic study. ACTH<sub>4-7</sub>-PGP was dissolved in normal saline (0.9% sodium chloride solution) and injected once intraperitoneally 15 min before the start of the experiment. ACTH<sub>6-9</sub>-PGP was also dissolved in normal saline and administered in a similar manner. The choice of doses was based on literature data on an ACTH<sub>4-7</sub>-PGP effective dose range (Dolotov et al. 2006, Koroleva and Myasoedov 2018). The control animals were injected with the equivalent volumes of normal saline at the rate of 1 ml per 1 kg of body weight.

Study design

The animals were divided into groups of 15 animals each, depending on a type and dose of the peptide obtained: 1 – control (normal saline of 0.9% sodium chloride solution); 2–0.5 μg/kg of ACTH<sub>4-7</sub>-PGP; 3–5 μg/kg of ACTH<sub>4-7</sub>-PGP; 4–50 μg/kg of ACTH<sub>6-9</sub>-PGP; 5–150 μg/kg of ACTH<sub>6-9</sub>-PGP; 6–450 μg/kg of ACTH<sub>6-9</sub>-PGP; 7–50 μg/kg of ACTH<sub>4-7</sub>-PGP; 8–150 μg/kg of ACTH<sub>4-7</sub>-PGP; and 9–450 μg/kg of ACTH<sub>4-7</sub>-PGP. All the studies were carried out from 9 am to 3 pm.

Test of passive avoidance conditioning (PAC)

During the experiment, the animals were placed in a shuttle box experimental unit (PanLab Harvard Apparatus, Spain), consisting of two chambers 25×25×28 cm in size, separated by an automatic guillotine door (8×10 cm). One compartment was brightly lit, whereas the other was dark, with an electric grid floor. An animal was placed in the illuminated compartment and allowed to examine it for 30 seconds, with the guillotine door closed. At the end of the familiarization time, the guillotine door between the compartments was automatically lifted, and after that, a latent period (LP) of the animal’s transition from the light compartment into the dark compartment was recorded. After
the animal entering the dark compartment, the guillotine door was closed, and the animal, after a short 2-second delay, was exposed to an electric current (0.8 mA) for 10 seconds (Trabace et al. 2000; Mironov 2012). The trained animals were considered to be the rats, which never again entered the dark compartment after having been exposed to an electric current. Untrained rats were excluded from the experiment. The total time spent by the rats in the shuttle box was 180 sec. The studied peptides were injected immediately after training in order to assess their effect on the processes of memory consolidation.

Twenty-four hours after exposure to the electric current, the animal was again placed in the lit compartment, and the LP of the animal’s re-entry into the dark compartment (avoidance delay) was fixed. The test for memory consolidation lasted for 180 seconds, after which the animal was removed from the experimental unit (Trabace et al. 2000; Mironov 2012).

### Statistical analysis

A statistical data analysis was performed using the Microsoft Excel 2016 software (Microsoft, USA), Statistica 13.3 software (TIBCO Software Inc., USA), and R Foundation for Statistical Computing (Vienna, Austria). The type of sample data distribution was determined using the Shapiro-Wilk test; the homogeneity of variance was verified using the Levene’s test (lawt package). The results obtained were reported as the median (Me), lower (25) and upper (75) quartiles (Q1 and Q3). The significance of the data differences was assessed using a non-parametric one-way analysis of variance by means of the Kruskal-Wallis test; the Mann-Whitney test (U-test) with Benjamini-Hochberg correction procedure was used to identify intergroup differences as a post-hoc analysis. Fisher’s exact test was used to compare qualitative characteristics in the independent groups. The significance level (p-value) when testing statistical hypotheses was taken equal to 0.05.

### Results and discussion

In the course of the experiment, when evenly distributing the trained animals within the experimental groups, the retention of avoidance conditioning varied in the animals 24 hours after the training, depending on the dose and a type of administered peptide (Table 1). Wherein the greatest avoidance conditioning retention was observed after the administration of ACTH$_{4-7}$-PGP at a dose of 0.5 μg/kg and ACTH$_{6-9}$-PGP at a dose of 50 μg/kg. These values exceeded those of the control animals by 2 times, and the differences were statistically significant. However, it is worth noting that the dose of ACTH$_{6-9}$-PGP was 100 times less than that of the reference peptide. At other doses, the intensity of ACTH$_{6-9}$-PGP effects was comparable to that of ACTH$_{4-7}$-PGP at a dose of 450 μg/kg. The proportion of rats with a retained avoidance conditioning was actually at the level of the control group when ACTH$_{6-9}$-PGP was applied at a dose of 150 μg/kg.

It was found that ACTH$_{6-9}$-PGP at doses from 0.5 μg/kg to 150 μg/kg had a pronounced effect on the consolidation of the avoidance conditioning by significantly increasing the latent period of the animal entering the dark chamber (Table 2). For example, the introduction of the peptide at a dose of 0.5 μg/kg led to a statistically significant increase in this indicator by 9 times (p = 0.004). Increasing in an ACTH$_{6-9}$-PGP dose to 5 μg/kg was accompanied by retaining the obtained effect, and the latent period of entering the dark chamber increased by 7 times (p = 0.05). At doses of 50 μg/kg and 150 μg/kg, this indicator assessing the memory consolidation processes also significantly differed from that in the control group animals, which was reflected in a 9-fold increase in the latent period of entering the dark chamber (p = 0.03). However, the subsequent increase in an ACTH$_{6-9}$-PGP dose to 450 μg/kg was accompanied by leveling of the previously revealed effect. Against the background of a tendency towards an increase in latent period duration, no statistically significant differences from the control group of animals were found (p = 0.1).

### Table 1. Indicators of Memory Trace Formation and Retention in Rats in PAC Test.

| Dose, μg/kg | Animals, % total | Number of trained animals | Retention of conditioning after 24 hours |
|------------|-----------------|--------------------------|----------------------------------------|
|            | abs | %          | abs | %               |
| control   | 15  | 11 | 73.3 | 5  | 45.5          |
| ACTH$_{4-7}$-PGP |     |        |      |                |
| 0.5       | 15  | 11 | 73.3 | 10 | 90.9*         |
| 5         | 15  | 11 | 73.3 | 7  | 63.6          |
| 50        | 15  | 11 | 73.3 | 8  | 72.7          |
| 150       | 15  | 11 | 73.3 | 7  | 63.6          |
| 450       | 15  | 11 | 73.3 | 7  | 70.0          |
| ACTH$_{6-9}$-PGP |     |        |      |                |
| 50        | 15  | 11 | 73.3 | 10 | 90.9*         |
| 150       | 15  | 10 | 66.7 | 5  | 50.0          |
| 450       | 15  | 10 | 66.7 | 7  | 70.0          |

Note: * – p<0.05-0.01 (according to the Fisher’s exact test).

### Table 2. Influence of ACTH$_{6-9}$-PGP and ACTH$_{4-7}$-PGP on Latent Period of Animal Entering the Dark Chamber (Me [Q1; Q3]).

| Indicator          | Latent period, sec |
|--------------------|--------------------|
| Dose, μg/kg        | 1st day | 2nd day |
| Control            | 14.6 [5.9; 37.1]  | 31.7 [17.5; 180] |
| ACTH$_{6-9}$-PGP   |         |         |
| 0.5                | 11.3 [10.2; 17.4] | 180.0 [180; 180] |
| 5                  | 21.5 [10.4; 39.7] | 180.0 [35.2; 180] |
| 50                 | 15.1 [8.2; 17.4]  | 180.0 [28.6; 180] |
| 150                | 6.0 [5.6; 14.2]   | 180.0 [15.8; 180] |
| 450                | 9.8 [5.8; 21.2]   | 180.0 [36.3; 180] |
| ACTH$_{4-7}$-PGP   |         |         |
| 50                 | 16.0 [7.9; 24.9]  | 180.0 [180; 180] |
| 150                | 16.2 [9.3; 22.8]  | 48.6 [19.6; 180] |
| 450                | 13.0 [8.1; 14]    | 180.0 [180; 180] |

Note: * – p<0.05-0.01.
the dark chamber was recorded at doses of 50 μg/kg and 450 μg/kg (p = 0.006 and p=0.01, respectively). Wherein no significant effects of the peptide were revealed at a dose of 150 μg/kg.

Our study showed that ACTH$_{4-7}$-PGP has a pronounced stimulating effect on the consolidation of the passive avoidance conditioning in rats in the dose range from 0.5 μg/kg to 150 μg/kg. Wherein there are literature data on the peptide positive effect on other learning and memory processes (fixation and reproduction of a memory trace in the PAC test) at only one dose – 50 μg/kg (Levitskaya et al. 2019). Taken together, these literature data and the results of our work indicate the ACTH$_{4-7}$-PGP effect on various phases of memory. We also showed that the reference peptide ACTH$_{6-9}$-PGP has a stimulating effect on learning processes at doses of 50 μg/kg and 450 μg/kg, which is consistent with the literature data (Koroleva and Myasoedov 2018; Levitskaya et al. 2019). However, a number of studies showed that ACTH$_{6-9}$-PGP at doses below 15 μg/kg with the intraperitoneal administration loses its ability to exert a nootropic effect (Koroleva and Myasoedov 2018). Therefore, high efficiency of ACTH$_{6-9}$-PGP on the consolidation of the avoidance conditioning at doses much lower than 15 μg/kg indicates its greater activity in relation to this process.

A wide range of effective doses is important for the development of pharmacological drugs based on regulatory peptides. It is known that the recommended method for their administration (e.g. for Semax) is intranasal. The amount of peptide entering the body using such a mode of administration can vary significantly due to a number of different circumstances. Under the experimental conditions, it was shown that the drug losses could be up to 85% during the intranasal administration (Makarenko et al. 2009; Wang-Fischer 2009). Therefore, it can be assumed that the pharmacological effects of a peptide with a wide range of low effective doses will be more pronounced and stable, and the ACTH$_{6-9}$-PGP peptide appears to be a more effective molecule than ACTH$_{4-7}$-PGP for influencing the processes of memory trace consolidation.

A higher intensity of the effects of ACTH$_{6-9}$-PGP in comparison with that of ACTH$_{4-7}$-PGP was also found in the study of its influence on temperature pain sensitivity (Dodonova et al. 2020), antidepressant activity (Dodonova et al. 2019), an anxiety level in the punished and unpunished behavior (Dodonova et al. 2020). Therefore, the data obtained in this work are consistent with the previously obtained results indicating the polyfunctional character of the neurotropic action of ACTH$_{6-9}$-PGP and its greater intensity in comparison with ACTH$_{4-7}$-PGP.

One of the mechanisms of the established ACTH$_{6-9}$-PGP nootropic action may be an increase in the content of neurotrophic factors in the brain. These factors are known to affect the growth and differentiation of nerve cells, as well as to stimulate the synthesis of various biologically active substances. In addition, neurotrophic factors, mainly BDNF (brain-derived neurotrophic factor), are involved in learning and the formation of a memory trace in the mammalian brain (Dolotov et al. 2006; Dmitrieva et al. 2010; Koroleva and Myasoedov 2018; Korolkin et al. 2019). It is important to note that the BDNF level significantly increases only 3 hours after the administration of ACTH analogs, in particular, ACTH$_{6-9}$-PGP, which indicates its participation only in delayed mechanisms of memory formation, including the consolidation of the memory trace.

It should also be noted that the functional activity of the biogenic amines system increases after the introduction of ACTH fragments. In particular, there is evidence in the literature about the effect of ACTH$_{6-9}$-PGP on serotonin and dopamine metabolisms, which can improve attention, release significant stimuli, improve motivation, and accelerate learning (Koroleva and Myasoedov 2018). However, in the literature, there are currently no experimental data either on the effect of ACTH$_{6-9}$-PGP on the state of the brain neurotransmitter systems or on the content of neurotrophic factors.

At the same time currently there are no data on the participation of the known MCRs in the implementation of the nootropic effect (Hoogduijn et al. 2002, Hruby et al. 2011). Therefore, to date, the question of the action of ACTH analogs through MCRs is still open, and it is assumed that there is at least one more undescribed subtype of receptors, through binding to which their nootropic effects can be realized (Dolotov et al. 2004).

**Conclusion**

The administration ACTH$_{6-9}$-PGP in the dose range from 0.5 μg/kg to 150 μg/kg has a pronounced stimulating effect on the processes of memory consolidation in the PAC test. The range of effective doses of ACTH$_{6-9}$-PGP
is narrower than that of ACTH$_{6-9}$-PGP, which indicates its greater activity in relation to this process. Therefore, based on the results obtained, ACTH$_{6-9}$-PGP can be considered as a promising molecule for creating pharmacological drugs with a nootropic effect.

The study results also expand the data on the biological effects of the N-terminal analogs of ACTH and may serve as a theoretical basis for the development of new pharmacological drugs with the nootropic action.

**Conflict of interests**

The authors declare no conflict of interests.

**References**

- Catania A (2008) Neuroprotective actions of melanocortins: a therapeutic opportunity. Trends in Neurosciences 31(7): 353–360. https://doi.org/10.1016/j.tins.2008.04.002 [PubMed]
- Catania A, Lonati C, Sordi A, Carlin A,Leonardi P, Gatti S (2010) The melanocortin system in control of inflammation. The Scientific World Journal 10: 1840–1853. https://doi.org/10.1100/tsw.2010.173 [PubMed]
- Clark AJ, Forfar R, Hussain M, Jerman J, McIver E, Taylor D, Chan L (2016) ACTH antagonists. Frontiers in Endocrinology (Lausanne) 7: 101. https://doi.org/10.3389/fendo.2016.00101 [PubMed]
- Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV (2010) Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and Molecular Neurobiology 30(1): 71–79. https://doi.org/10.1007/s10571-009-9432-0 [PubMed]
- Dodonova SA, Bobyntsev II, Belykh AE, Andreeva LA, Myasoedov NF (2019) Changes in the nociceptive response to thermal stimulation in rats following administration of N-terminal analogs of the adrenocorticotropic hormone. Bulletin of Russian State Medical University 6: 33–36. https://doi.org/10.24075/vrgmu.2019.085
- Dodonova SA, Bobyntsev II, Belykh AE, Anfilova MG, Andreeva LA, Myasoedov NF (2019) Comparative study of anti-depressant activity of N-terminal analogs of adrenocorticotropic hormone in rats. Kursk Scientific and Practical Bulletin “Man and Health” [Kurski Nauchno-Prakticheskiy Vestnik “Chelovek i Ego Zdorov”] 4: 83–89. https://doi.org/10.21626/vestnik/2019-4/10 [in Russian]
- Dodonova SA, Bobyntsev II, Belykh AE, Telegina IA, Muzaleva YuA, Andreeva LA, Myasoedov NF (2020) Effects of peptides ACTH$_{6-9}$-PGP and ACTH$_{6-9}$-PGP on anxiety levels in rats in punished and unpunished behavior. Neuroscience and Behavioral Physiology 50(9): 1203–1208. https://doi.org/10.1007/s11055-020-01022-w
- Dolotov OV, Karpenko EA, Inozemtseva LS, Sereindina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LYu, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J (2006) Semax, an analog of ACTH(4-10) with cognitive activity of N-terminal analogs of adrenocorticotropic hormone in rats. Kursk Scientific and Practical Bulletin “Man and Health” [Kurski Nauchno-Prakticheskiy Vestnik “Chelovek i Ego Zdorov”] 4: 83–89. https://doi.org/10.21626/vestnik/2019-4/10 [in Russian]
- Fridmanis D, Roga A, Klovinas I (2017) ACTH receptor (MC2R) specificity: What do we know about underlying molecular mechanisms? Frontiers in Endocrinology (Lausanne) 8: 13. https://doi.org/10.3389/fendo.2017.00013 [PubMed]
- Hill JW, Faulkner LD (2017) The role of the melanocortin system in metabolic disease: New developments and advances. Neuroendocrinology 104(4): 330–346. [https://doi.org/10.1159/000450649 [PubMed]
- Hoogduijn MJ, McGurk S, Smit NP, Nibbering PH, Ancans J, van der Laarse A, Thody A (2002) Ligand-dependent activation of the melanocortin 5 receptor: cAMP production and ryano dine receptor-dependent elevations of [Ca(2+)](I). Biochemical and Biophysical Research Communications 290(2): 844–850. doi.org/10.1006/brbc.2001.6283 [PubMed]
- Hruby VJ, Cai M, Cain J, Nyberg J, Trivedi D (2011) Design of novel melanocortin receptor ligands: multiple receptors, complex pharmacology, the challenge. European Journal of Pharmacology 660(1): 88–93. https://doi.org/10.1016/j.ejphar.2010.10.109 [PubMed]
- Korokin MV, Soldatov VO, Tietze AA, Golubev IV, Belykh AE, Kubekina MV, Puchenkova OA, Denisyuk TA, Gureyev VV, Pokrovskaya TG, Guadyres OS, Zhuchenko MA, Zatolokina MA, Pokrovskiy MV (2019) 11-Amino acid peptide imitating the structure of erythropoietin α-helix B improves endothelial function, but stimulates thrombosis in rats. Pharmacy and Pharmacology [Farmatsiya i Farmakologiya] 7(6): 312–320. https://doi.org/10.19163/2307-9266-2019-7-6-312-320
- Koroleva SV, Myasoedov NF (2018) Semax as a universal drug for therapy and research. Biology Bulletin 45(6): 589–600. https://doi.org/10.1134/S1062359018060055
- Levitkaya NG, Glazova NYu, Starobinska EA, Manchenko DM, Andreeva LA, Kamensky AA, Myasoedov NF (2019) Nootropic and anxiolytic effects of heptapeptide ACTH6-9-Pro-Gly-Pro. Russian Journal of Physiology [Rossiyskiy Fiziolohicheskiy Zhurnal im. I.M. Sechenova] 105(6): 761–770. https://doi.org/10.1134/S0869813919060049 [in Russian]
- Levitkaya NG, Kamensky AA (2009) Melanocortin system. Progress in Physiological Science [Uspekhi Fiziolohicheskih Nauk] 40(1): 44–65. [in Russian]
- Makarenko IE, Avdeeva Ol, Yvanit GV, Rybakova AV, Khodko SV, Makarova MN, Makarov VG (2013) Possible ways of administration and standard drugs in laboratory animals. International Bulletin of Veterinary Medicine [Mezhdunarodnyy Vestnik Veterinarii] 3: 78–84. [in Russian]
- Mironov AN (2012) Guidelines for Preclinical Studies of Drugs. Part one. Moscow, 944 pp. [in Russian]
Author contributions

Svetlana A. Dodonova, Assistant lecturer of the Department of Pathophysiology, e-mail: dodonovasveta@mail.ru, ORCID ID https://orcid.org/0000-0001-8491-3082. The author collected processed and analyzed the data, and wrote this manuscript.

Igor’ I. Bobyntsev, Doctor Habil. of Medicine, Professor, Head of the Department of Pathophysiology, e-mail: bobig@mail.ru, ORCID ID https://orcid.org/0000-0001-7745-2599. The author conceived and designed the study and wrote this manuscript.

Andrey E. Belykh, PhD, Associate Professor of the Department of Pathophysiology, e-mail: a.e.belykh@gmail.com, ORCID ID https://orcid.org/0000-0001-9766-2104. The author collected, processed and analyzed the data, and wrote this manuscript.

Anton O. Vorvul’, Junior researcher of the Research Institute of General Pathology, PhD student of the Department of Pathophysiology, e-mail: vorvul1996@mail.ru, ORCID ID https://orcid.org/0000-0002-1529-6014. The author collected, processed and analyzed the data, and wrote this manuscript.